

Apotmex – Recall of enoxaparin injection

- On February 2, 2021, [Apotex announced](#) a voluntary, consumer level recall of two lots of [enoxaparin injection](#) due to a packaging error resulting in some syringes barrels containing 150 mg/mL markings (corresponding to 120 mg/0.8mL strength) instead of 100 mg/mL markings (corresponding to 100 mg/mL strength) on the syringe barrel and vice versa.
- The recalled lots are listed below:

Product Description	NDC#	Lot# (Expiration Date)
Enoxaparin sodium injection, 100 mg/mL, 10 x 1 mL single dose syringes	60505-0795-4 (# on carton)	CS008 (4/2022)
	60505-0795-1 (# on syringe)	
Enoxaparin sodium injection, 120 mg/0.8 mL, 10 x 0.8 mL single dose syringes	60505-0796-4 (# on carton)	CT003 (5/2022)

- Enoxaparin is indicated for the prophylaxis of deep vein thrombosis, treatment of acute deep vein thrombosis, prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction (MI), and for the treatment of acute ST-segment elevation MI.
- Incorrect syringe barrel marking could lead to miscalculation and inaccurate dose administration to patients.
 - In lot CS008 (strength 100 mg/mL), if a consumer used a 150 mg/mL concentration packaged in a barrel corresponding to a 100 mg/mL concentration, patients could receive 3.75 mg of enoxaparin, instead of 3 mg of enoxaparin.
 - In lot CT003 (strength 120 mg/0.8mL), if a consumer used a 100 mg/mL concentration packaged in a barrel corresponding to a 150 mg/mL concentration, patients would receive 2 mg of enoxaparin rather than 2.5 mg of enoxaparin.
- Accidental overdosage or underdosage following administration of enoxaparin injection may lead to bleeding complications or blood clotting conditions, respectively.
- To date, Apotex has not received reports of any adverse events or identifiable safety concerns attributed to use of the recalled lots.
- Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to the recalled enoxaparin injection.
- Anyone with an existing inventory of the recalled product should stop use, distribution and quarantine the product immediately.

- Contact Apotex by phone at **1-800-706-5575** or by email at UScustomerservice@Apotex.com for more information about this recall. Contact Inmar (appointed company for Apotex) at **1-855-667-8717** for return and refund information.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.